Session Number:
17
Session Title:
Cancer/Tumor Markers
Session Type:
Poster
Session Start:
7/27/2006 9:30:00 AM
Session End:
7/27/2006 12:00:00 PM
Location:
Presentations:
Alessandra Barassi --
E-1. The search of the stool and blood K-ras mutations in patients with pancreatic mass. A prospective study
Alexandra R. Belous --
E-2. Mass Spectrometric Analysis of Estrogen-DNA Adducts
FRANCESCA DI SERIO --
E-3. Mesothelin-family proteins and diagnosis of mesothelioma: analytical evaluation and preliminary clinical results
Romolo M. Dorizzi --
E-4. Diagnostic Odds Ratios of different S-100 B protein concentrations in the follow-up of malignant melanoma
David K. Dosoo --
E-5. Prostate specific antigen (PSA) levels in health, prostatic carcinoma and benign prostatic hyperplasia
Michael Evelegh --
E-6. A Microwell-Based Galactose Oxidase-Schiff's Assay for Thomsen-Friedenreich Antigen in Diagnosis of Lung Cancer
Thomas G. EWART --
E-7. Fifteen minute intra-operative microarray parathyroid hormone assay with internal calibration standard subarray for parathyroid tumor surgery.
Jennifer S. Fenske --
E-8. Development of a Sensitive, Automated Calcitonin Assay on the LIAISON® Immunoassay Analyzer
Deanna DH. Franke --
E-9. Analysis of Immunoglobulin Free Light Chains in Urine: A Sensitive Assay to Characterize Bence Jones Proteinuria
Yunchao Gao --
E-10. Tumor markers in metastatic liver cancer of gastrointestinal origin
Peter J. Hamer --
E-11. Serum EGFr and HER-2/neu Predicts Poor Survival in Metastatic Breast Cancer
Peter J. Hamer --
E-12. Elevated Plasma TIMP-1 Level Predicts Decreased Response and Survival in Metastatic Breast Cancer
Hiroyuki Hanada --
E-13. Root cause analysis on CA19-9 measurement discrepancies of four commercially available kits and clinical accuracy in pancreas cancer diagnosis
Andrew N. Hoofnagle --
E-14. Reducing autoantibody interference in thyroglobulin testing.
Kenneth U. Ihenetu --
E-15. Digitalis and ouabain compounds as novel therapies for malignant lymphoblastic disease.
Annette John-Baptiste --
E-16. Performance Characteristics of an EIA Kit for Determining Survivin in Plasma
Sonia L. La'ulu --
E-17. Evaluation of Five Automated CA 19-9 Assays
Sandra A.. Lewisch --
E-18. QUANTITATION OF TUMOR MARKERS BY LOCI™ REAGENT TECHNOLOGY ON THE DIMENSION VISTA™ INTELLIGENT LAB SYSTEM
Shu-Ling Liang --
E-19. A Pharmacoproteomic Approach to Evaluate the Effects of an Epidermal Growth Factor Receptor Inhibitor on Tumor Tissues.
Hankui Lu --
E-20. Evaluation of novel protein-chip detection for serum multi-tumor markers
Hankui Lu --
E-21. Clinical validation of protein-chip-A detection for multi-tumor markers
Gian Vico V. Melzi d'Eril --
E-22. Evaluation of calprotectin in colonic polyposis. A preliminary study
Mohammad Muzaffar. Mir --
E-23. Studies on genetic alterations in p53, ß-catenin and Raf genes in squamous cell carcinoma of esophagus in Kashmir valley (India).
Rama D. Mittal --
E-24. Inter-relationship between prostate specific antigen,kallikrein-2 and androgen receptor gene polymorphisms with risk of prostate cancer in India.
Ross J. Molinaro --
E-25. Identification of RNA Activators of a Novel Tumor Suppressor Pathway in Prostate Cancer Cells
Ricardo Moro --
E-26. High Discrimination Between Prostate Cancer, Benign And Normal Serum Samples Using The Cancer Marker RECAF.
Matthew Nutter --
E-27. Comparison of Plasma to Serum Results for the Abbott ARCHITECT® Total PSA and Free PSA Assays
Tomris Ozben --
E-28. THE RELATION OF CYTOKINES, SERUM INSULIN AND INSULIN RESISTANCE WITH THE PROGRESSION FREE SURVIVAL AND OVERALL SURVIVAL OF METASTATIC BREAST CANCER PATIENTS
Tomris Ozben --
E-29. DIVERSE EFFECTS OF ANTIOXIDANTS ON THE CYTOTOXICITY OF CHEMOTHERAPEUTIC DRUGS
Jacques Passagot --
E-30.
Performance Evaluation of a New VIDIA® tPSA Assay
Carol M. Preissner --
E-31. A New Immunochemiluminometric Assay for Chromogranin A in Serum Samples
Carol M. Preissner --
E-32. Evaluation of the Immutopics Human FGF-23 (C-Term) ELISA Kit
Richard Prusa --
E-33. Increase in content of metallothionein as marker of resistence to cisplatin treatment
Richard Prusa --
E-34. Study of interaction of glutathiones and metallothionein with cytostatics
Alex J. Rai --
E-35. Proteomic Analysis of Haptoglobin alpha-subunit Isoelectric variants as Ovarian Cancer Biomarkers using Narrow Range Two Dimensional Gel Electrophoresis and Immunoblotting
Paul Ravetto --
E-36. Sensitive and Selective Assays for Mutations in EGFR
Steven D. Reid --
E-37. Screening for monoclonal gammopathy: inclusion of serum free light chain immunoassays produce an increased detection rate
Steven D. Reid --
E-38. MGUS incidence in a chronic kidney disease population
Marie-Pierre Roger --
E-39. PERFORMANCE EVALUATION OF AN AUTOMATED IMMUNOASSAY FOR THE DETERMINATION OF PSA (Prostate Specific Antigen) ON THE OLYMPUS AU3000i™ IMMUNOASSAY SYSTEM
Batool Shannan --
E-40. Clusterin over-expression protects against the antiproliferative effects and the apoptosis induced by 1,25(OH)2D3 in LNCaP in vitro
Paul J. Showell --
E-41. Evaluation of latex-enhanced turbidimetric reagents for measurement of free immunoglobulin light-chains on The Binding Site automated analyser
Krystyna Sztefko --
E-42. Plasma hsCRP level before and six months after surgery in colon cancer patients
Krystyna Sztefko --
E-43. Insulin-like growth factor binding protein-2 (IGFBP2), CEA and Ca19-9 in monitoring colon cancer patients
Jill R. Tate --
E-44. Clinical Utility and Technical Pitfalls of the Serum Free Light Chain (FLC) Assay for Monitoring of Monoclonal Light-Chain Diseases
Charles F. Weinzierl --
E-45. Analytical Performance of the Access BPH-A Assay from Beckman Coulter
Steven J. Zibrat --
E-46. Analytical and Clinical Evaluation of Low Concentration Prostate Specific Antigen Measurements on the Roche/Hitachi MODULAR Analytics E170 System for Post-Treatment Monitoring
I hate to bust your bubble about Abbott following Moro but that is not what is going on.
This is how "Poster Sessions" work:
You are in a meeting hall, and in this case, with 46 individual booths. In this session, attendees can browse the various booths and view the information "posted" in the booths. Dr. Moro and possibly others will be in the booth to answer any questions the attendees have that traffic the booth. There is NO formal presentation in this situation. The booths have been assigned according to the last name of the presenter.
BTW, designing posters for these presentations is an industry in itself. You cannot afford to waste your money for a booth and have a poor presentation that does not catch the attention of attendees passing by.
